---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007396"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:46:09.208365+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Soligenix obtains exclusive option for Phase 2/3-ready topical Pentoxifylline in Behçet's Disease

## Summary
- Exclusive option agreement with Silk Road Therapeutics to acquire topical Pentoxifylline for mucocutaneous ulcers in Behçet's Disease.
- BD affects ~18,000 US, 80,000 EU patients; orphan disease with no cure, current treatments limited.
- Phase 2 trial showed 83% of PTX patients had ulcer shrinkage by Day 2 vs 19% colchicine (p<0.0001).
- By Day 4, 72% on PTX had undetectable ulcer vs 29% colchicine; no serious adverse events.
- Program is Phase 2/3-ready; Soligenix plans FDA discussions on trial design.

## SEC filing metadata
- accession: 0001558370-23-007396
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000155837023007396/0001558370-23-007396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000155837023007396/sngx-20230501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007396
- JSON: https://secwatch.observer/filing/0001558370-23-007396.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.